Potentials of Polymeric Nanocarriers Loaded with Clarithromycin for Antibacterial Activity
Open Access
- 30 December 2022
- journal article
- review article
- Published by Lattice Science Publication (LSP) in International Journal of Advanced Pharmaceutical Sciences and Research
- Vol. 3 (1) , 1-4
Abstract
Clarithromycin (CTM) is a semisynthetic derivative of erythromycin that have been reported to exhibit potential antibiotic activities mostly against the gram-negative and gram-positive bacteria, lower/upper respiratory tract and skin infection causing pathogens. It is widely used for the prevention and management of infections due to Mycobacterium avium complexes and peptic ulcers due to Helicobacter pylori. Various marketed formulation of CTM in the form of tablets, capsules and other conventional dosage forms is available as anti-infective, however the drug itself has several limitations. These limitations include low oral bioavailability, rapid metabolism, poor targeting to infected sites and toxicity to normal cells/tissues. Also, the CTM-based therapy has been reported for several gastrointestinal adverse effects, including diarrhea, stomach upset, gastric distress, atypical taste, and others. Thus, to overcome these issue, various novel strategies including nanotechnology or nanocarrier-based approaches have showed significant effects and have been immensely considered worldwide. In recent years, the various nanocarriers or nanocarrier-based delivery systems, particularly the polymeric nanocarrier have played significant role in effective drug targeting. Thus, in this review, the various polymeric nanocarrier-based delivery systems of CTM that effective reduced the dosing frequency, improved the patient compliance and potentially enhanced the therapeutic efficiency of CTM has been summarized.Keywords
This publication has 21 references indexed in Scilit:
- A study on enhanced intestinal permeability of clarithromycin nanoparticlesBrazilian Journal of Pharmaceutical Sciences, 2014
- Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistantStaphylococcus aureusinfectionDrug Delivery, 2013
- Interplay of Degradation, Dissolution and Stabilization of Clarithromycin and Its Amorphous Solid DispersionsMolecular Pharmaceutics, 2013
- Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery systemColloids and Surfaces B: Biointerfaces, 2011
- pH-sensitive hydrogels based on semi-interpenetrating network (semi-IPN) of chitosan and polyvinyl pyrrolidone for clarithromycin releaseDrug Development and Industrial Pharmacy, 2011
- Lectin Conjugated Gastroretentive Multiparticulate Delivery System of Clarithromycin for the Effective Treatment of Helicobacter pyloriMolecular Pharmaceutics, 2008
- Formulation and Evaluation of Gastroretentive Dosage Forms of ClarithromycinAAPS PharmSciTech, 2008
- Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H. pyloriJournal of Controlled Release, 2008
- Effects of combining extracts (from propolis or Zingiber officinale) with clarithromycin on Helicobacter pyloriPhytotherapy Research, 2006
- Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humansAntimicrobial Agents and Chemotherapy, 1990